ERBB2 and breast carcinoma: Data from clinical studies has shown that the majority of HR+/HER2+ breast cancer patients are minimally responsive to endocrine therapy and it is also well known that HER2 positivity plays a critical role in the resistance to hormonal therapy[18,19].